DELTA – integrateD diagnostic solution for EarLy deTection of oesophageal cAncer.
Project DELTA will assess the feasibility and practical implementation steps of introducing CytospongeTM – TFF3 as a triage test for endoscopy to identify Barrett’s oesophagus, early cancer and other oesophageal conditions.
BEST2 – Evaluation of a Non-Endoscopic Immunocytological Device (Cytosponge) for Barrett’s Esophagus Screening in a Case-Control Study (BEST2).
The Barrett’s oEsophagus Screening Trial is looking at whether a new device called the Cytosponge coupled with a molecular test would offer a suitable alternative to diagnose Barrett’s Oesophagus in the general population.
https://www.mrc-cu.cam.ac.uk/research/rebecca-fitzgerald/clinical-studies/BEST2Folder
